LGND

Business Context and Reporting Period

Ligand Pharmaceuticals Inc. (LGND) is a biopharmaceutical royalty company focused on acquiring and creating diversified royalty streams from high-value medicines. The company operates two infrastructure-light platform technologies, Captisol and NITRICIL, and maintains a portfolio of over 90 commercial and development-stage programs. This Form 10-K covers the fiscal year ended December 31, 2025.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 60% to $268.1 million, driven by a 48% increase in royalties ($161.0 million) and a 143% increase in contract revenue ($66.9 million). Royalty growth was primarily due to the Q3 2024 acquisition of Qarziba financial royalty assets and increased sales of Filspari, Ohtuvayre, and Capvaxive.
• Profitability: The company returned to profitability with $124.5 million in net income, compared to a $4.0 million net loss in 2024. This turnaround was significantly aided by a $90.7 million gain from the change in fair value of equity method investments (primarily Pelthos) and a $53.1 million gain from the Pelthos Transaction.
• Strategic Transactions:
  • Pelthos Transaction: In July 2025, Ligand merged its wholly-owned subsidiary LNHC, Inc. with Channel Therapeutics to form Pelthos Therapeutics. Ligand recognized $53.1 million in income and retains approximately 48% of Pelthos common stock and 60% of Series A preferred stock.
  • Debt Issuance: In August 2025, Ligand issued $460 million in aggregate principal amount of 0.75% Convertible Senior Notes due 2030, netting approximately $445.1 million in proceeds.
  • Investments: Significant R&D funding arrangements were entered into with Castle Creek Biosciences ($50 million) and Orchestra BioMed ($25 million initial funding), resulting in increased R&D expenses.
• Impairments: Financial royalty asset impairment decreased to $6.2 million in 2025 from $30.6 million in 2024. The 2025 impairment was primarily related to Agenus partner programs, while the 2024 impairment was driven by Takeda's discontinuation of the soticlestat program.

Guidance, Outlook, and Risks

• Outlook: Management expects continued revenue growth driven by the commercialization of new assets like Zelsuvmi (launched July 2025) and Ohtuvayre, as well as the expansion of the Captisol platform. The company maintains a disciplined capital allocation strategy focused on high-margin, low-infrastructure royalty assets.
• Key Risks:
  • Partner Reliance: Revenue is heavily dependent on the sales performance and solvency of partners (e.g., Amgen, Merck, Recordati). Recordati represents 54% of financial royalty assets.
  • Generic Competition: Key products face generic entry risks. A settlement allows Teva to market a generic version of Evomela in the U.S. starting June 1, 2026. Generic Kyprolis is expected to launch in 2027 or sooner.
  • Regulatory and Clinical: Success of development-stage assets (e.g., Qtorin rapamycin, D-Fi) depends on regulatory approvals and clinical trial outcomes.
  • Supply Chain: Captisol production relies on a single supplier, Hovione. Supply interruptions could materially impact revenue.

Investor Verification Checklist

• Pelthos Valuation: Verify the fair value assumptions used for the $90.7 million gain on Pelthos equity investments and the sustainability of this non-operating income stream.
• Generic Impact on Evomela: Assess the projected revenue decline for Evomela following the June 2026 generic entry by Teva.
• Debt Covenants: Review the minimum consolidated EBITDA covenant ($55 million) under the amended Revolving Credit Facility and the company's ability to maintain compliance.
• R&D Expense Sustainability: Evaluate the long-term impact of the $62.1 million in R&D funding expenses (Castle Creek and Orchestra) on future cash flows, as these are expensed upfront.
• Qarziba Performance: Monitor the commercial performance of Qarziba (Recordati), which was a primary driver of royalty growth in 2025.